# TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Source: https://onco.cc/trials/nct04701476/  
OnCo record `nct04701476` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab, Trifluridine/tipiracil, Regorafenib in colorectal cancer, run by Teclison Ltd., now recruiting.

## Summary

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC is a phase 2 interventional study registered as NCT04701476 by Teclison Ltd., with 110 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-03-31. Interventions recorded: TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill. Conditions listed: Colorectal Cancer; Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04701476
- Phase: 2
- Setting: An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
- Sponsor: Teclison Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT04701476: https://clinicaltrials.gov/study/NCT04701476

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Regorafenib](https://onco.cc/drugs/regorafenib/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)

---
JSON: https://onco.cc/api/v1/entities/nct04701476.json